39th National Congress of the Italian Society of Organ TransplantationRenal transplantationAnemia and Immunosuppressive Regimen in Renal Transplanted Patients: Single-Center Retrospective Study
Section snippets
Materials and Methods
In this retrospective study, we selected from our cohort of transplanted patients currently on follow up in our clinic 59 treated with Rad, Cya, and corticosteroids (CS), and 128 treated with Cya, MPA, and CS. All the transplantations were performed in our unit between 2006 and 2013 and compared Hb and percentage of patients affected by anemia in the 2 groups. Anemia was defined as Hb < 13 g/dL in men and <12 g/dL in women or need to use recombinant erythropoietin (rEPO). We also compared
Results
The 2 groups were comparable for baseline characteristics. We observed no difference in terms of Hb levels in patients treated with Rad (12.9 ± 1.6 vs 12.7 ± 1.5 g/dL). PTA was found in 49% and 45% of patients in the 2 groups, respectively (P = .6). The 2 groups had similar levels of serum creatinine, eGFR, ferritin, folic acid, and cyanocobalamin. Only the MCV was significantly lower in the Rad group, as expected. In the multivariate analysis only serum creatinine and eGFR have an influence on
Discussion
In this study we evaluated whether Rad-based therapy is associated with a higher risk of developing PTA with respect to MPA. Available data from literature regarding the issue of PTA and use of mTOR are mainly related to the use of SRL. In a review by Fishbane et al [5], the authors conclude that although SRL may be a contributing factor for PTA, it is impossible to dissect with any certainty its independent causative role from the combined effects of SRL administered along with other
Conclusions
In our study population, treatment with Rad was not associated with a higher percentage of patients with PTA.
References (13)
- et al.
Prevalence and management of anemia in renal transplant recipients: a European survey
Am J Transplant
(2003) - et al.
Posttransplant anemia: the role of sirolimus
Kidney Int
(2009) - et al.
Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients
Am J Transplant
(2004) - et al.
Strategies for the management of adverse events associated with mTOR inhibitors
Transplant Rev (Orlando)
(2014) - et al.
Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study
Am J Transplant
(2015) - et al.
Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results
Transplant Proc
(2008)
Cited by (3)
Risk factors and current state of therapy for anemia after kidney transplantation
2023, Frontiers in MedicinemTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant Recipients
2022, Frontiers in Medicine